telaprevir | 569364-34-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: telaprevir
• 英文别名: VX-950；VX-950, Telaprevir；(3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
• CAS: 569364-34-7
• 化学式: C₃₆H₅₃N₇O₆
• 分子量: 679.86
• InChiKey: BBAWEDCPNXPBQM-IGSHNTALSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  49
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  180
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  L-叔亮氨酸甲酯盐酸盐 在 盐酸 、 sodium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 生成 telaprevir
  参考文献：
  名称：

  P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-ketoamides as HCV protease inhibitors

  摘要：

  With the aim of improving HCV protease inhibitors reported in our previous manuscripts, we synthesized and evaluated a series of la-based tetrapeptidyl alpha-ketoamides with additional P4 modification. The promising analog discovered through this SAR, 5a, was further derivatized at P1' or P1 position. As a result of these efforts, we found that replacement of the P4 valine as seen in 1a with cyclohexylglycine (Chg) resulted in the discovery of 5a, 5c, and 5e endowed with improved cellular activity in comparison to 1a. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.007

文献信息

• [EN] PROCESS FOR THE SYNTHESIS OF PYRROLIDINES AND PYRROLES<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE PYRROLIDINES ET DE PYRROLES
  申请人：SANDOZ AG

  公开号：WO2014096374A1

  公开（公告）日：2014-06-26

  The invention relates to pyrrolidines, pyrroles and processes for the preparation of pyrrolidines and pyrroles.

  该发明涉及吡咯烷、吡咯烷和制备吡咯烷和吡咯烷的工艺。
• PEPTIDOMIMETIC PROTEASE INHIBITORS
  申请人：BABINE ROBERT EDWARD

  公开号：US20120282219A1

  公开（公告）日：2012-11-08

  The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

  本发明涉及肽类似物化合物，作为蛋白酶抑制剂，特别是作为丝氨酸蛋白酶抑制剂，更特别是作为丙型肝炎NS3蛋白酶抑制剂；以及其中间体；它们的制备，包括新的对中间体的立体选择性过程。本发明还涉及制药组合物，以及使用这些化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染相关的生理状况的患者的方法。还提供了药物组合物，其中除了一个或多个HCV丝氨酸蛋白酶抑制剂外，还包括一个或多个表现出抗HCV活性的干扰素和/或一个或多个具有抗HCV活性的化合物和一种药学上可接受的载体，并使用这些组合物来治疗或预防患者的HCV感染。本发明还涉及用于治疗或预防患者HCV感染的工具包或药物包。
• AGENT FOR TREATING HCV INFECTION
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2589595A1

  公开（公告）日：2013-05-08

  Provided is an imidazolylbenzene compound or salt thereof that controls HCV replication and in addition is particularly capable of strongly controlling HCV replication, and is very effective in the prevention and treatment of HCV infection when used in combination with another agent for treating HCV infection such as Interferon.

  本发明提供了一种咪唑基苯化合物或其盐，该化合物或其盐可控制 HCV 的复制，特别是能够强效控制 HCV 的复制，当与另一种治疗 HCV 感染的药物（如干扰素）联合使用时，可非常有效地预防和治疗 HCV 感染。
• Chimeric antigen receptor (CAR) modulation
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US11059864B2

  公开（公告）日：2021-07-13

  The technology described herein is directed to CAR polypeptides and systems comprising repressible proteases. In combination with a specific protease inhibitor, the activity of said CAR polypeptides and systems and cells comprising them can be modulated. Also described herein are methods of using said CAR polypeptides and systems, for example to treat various diseases and disorders.

  本文所述技术针对的是包含可抑制蛋白酶的 CAR 多肽和系统。结合特定的蛋白酶抑制剂，可以调节所述 CAR 多肽和系统以及包含它们的细胞的活性。本文还描述了使用所述 CAR 多肽和系统的方法，例如用于治疗各种疾病和失调。
• Regulated synthetic gene expression systems
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US11530246B2

  公开（公告）日：2022-12-20

  The technology described herein is directed to regulated synthetic gene expression systems. In one aspect described herein are synthetic transcription factors (synTFs) comprising a DNA binding domain, a transcriptional effector domain, and a regulator protein. In other aspects described herein are gene expression systems comprising said synTFs and methods of treating diseases and disorders using said synTFs.

  本文所述技术针对的是受调控的合成基因表达系统。一方面，本文所述的合成转录因子（synTFs）包括 DNA 结合结构域、转录效应结构域和调节蛋白。在其他方面，本文所述的基因表达系统包括所述的合成转录因子和使用所述合成转录因子治疗疾病和失调的方法。